AstraZeneca delivers milestone payment to StarPharma (ASX:SPL) for phase 1 trial
  • AstraZeneca has begun the phase 1 clinical trial for a cancer treatment drug
  • Roughly $4.29 million will be paid to StarPharma (SPL) as a result of the trial
  • The drug comes under a multi-product license for AstraZeneca to develop treatments using StarPharma's DEP drug delivery technology
  • StarPharma shares are trading 1.26 per cent higher today, currently priced at $1.21

AstraZeneca has commenced the phase 1 clinical trial of AZD0466, triggering a milestone payment to StarPharma (SPL).

The trial will include patients with various forms of cancers at four or five sites across the U.S.

AZD0466 acts on both solid and haematological tumours (blood cancers) by targeting oncology targets Bcl2 and Bcl/xL.

It is one of several products being developed by AstraZeneca under a multi-product licence using StarPharma's DEP drug delivery technology.

Under the 2015 agreement, AstraZeneca fully funds the development and commercialisation of AstraZeneca DEP products.

StarPharma will receive milestone payments up to nearly $177.5 million (US$124 million) for development, launch and sales milestones, in addition to tiered royalties on net sales.

Starpharma CEO Dr Jackie Fairley said the company is pleased AZD0466 has now entered clinical trials.

“It is really exciting to achieve this important milestone both for our collaboration with AstraZeneca and for Starpharma’s DEP® platform."

"This is our first partnered DEP® product to enter the clinic, alongside our three internal DEP® products; DEP® docetaxel, DEP® cabazitaxel and DEP® irinotecan," she said.

StarPharma shares are trading 1.26 per cent higher today, worth $1.21 at 11:06 am AEDT.


SPL by the numbers
More From The Market Herald
OBJ (ASX:OBJ) - CEO, Paul Peros - The Market Herald

" OBJ (ASX:OBJ) to raise $4.5M for product development and licencing

Innovative wellness company OBJ (OBJ) is aiming to raise $4.5 million through an entitlement offer and placement for licencing, development and general workin…
Creso Pharma (ASX:CPH) - CEO & Co Founder, Dr Miri Halperin Wernli (left) and Chairman, Boaz Wachtel (right) - The Market Herald

" Creso Pharma (ASX:CPH) subsidiary receives follow-up order from Univo Pharmaceuticals

Creso Pharma’s (CPH) subsidiary, Mernova Medicinal, has received a US$625,690 (roughly A$901,830) purchase order from Univo Pharmaceuticals.
Holista Colltech (ASX:HCT) - Managing Director, Dr Rajen Manicka - The Market Herald

" Holista CollTech (ASX:HCT) misses the mark for hand sanitiser product

Holista CollTech (HCT) has downgraded its $3.8 million in expected sales from its hand sanitiser product, Natshield, due to COVID-19 and race riots.
Cellmid (ASX:CDY) - CEO, Maria Halasz (right) - The Market Herald

" Cellmid (ASX:CDY) signs distribution agreement for SARS-CoV-2 and ELISA’s

Cellmid (CDY) has signed a distribution agreement with Immunodiagnostics (IMD) for Enzyme Linked Immunosorbent Assays (ELISA’s) and SARS-CoV-2 tests in Australia and New